December 2025 in “npj Breast Cancer” In the phase 3 CAPItello-291 trial, capivasertib combined with fulvestrant significantly increased progression-free survival in patients with advanced breast cancer with specific genetic alterations, but the authors highlight that managing side effects like diarrhea, rash, and hyperglycemia is crucial for optimizing treatment adherence and outcomes.
March 2025 in “Future Oncology” This study found that participants with HR-positive/HER2-negative advanced or metastatic breast cancer treated with sacituzumab govitecan had better quality of life and longer survival compared to standard chemotherapy recipients.
12 citations
,
February 2019 in “Journal of patient-reported outcomes” This study identified common symptoms and side effects experienced by women with hormone receptor-positive, HER2-negative advanced breast cancer, including fatigue, hair loss, and impacts on daily activities and mobility.
9 citations
,
April 2024 in “The Oncologist” This study found that sacituzumab govitecan improved health-related quality of life in most areas for patients with HR+/HER2− metastatic breast cancer compared to chemotherapy, except for increased diarrhea, supporting its use as a treatment option.
8 citations
,
June 2022 in “Cancers” In this study, EC chemotherapy was found to be noninferior to TC in causing grade 3 or 4 neutropenia among HR+/HER2-negative breast cancer patients, but EC was associated with more other adverse events.
